1
|
Couselo-Seijas M, Vázquez-Abuín X, Gómez-Lázaro M, Pereira L, Gómez AM, Caballero R, Delpón E, Bravo S, González-Juanatey JR, Eiras S. FABP4 Enhances Lipidic and Fibrotic Cardiac Structural and Ca 2+ Dynamic Changes. Circ Arrhythm Electrophysiol 2024; 17:e012683. [PMID: 39212041 DOI: 10.1161/circep.123.012683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 07/26/2024] [Indexed: 09/04/2024]
Abstract
BACKGROUND Adipocyte FABP4 (fatty acid-binding protein 4) is augmented in the epicardial stroma of patients with long-standing persistent atrial fibrillation. Because this molecule is released mainly by adipocytes, our objective was to study its role in atrial cardiomyopathy, focusing our attention on fibrosis, metabolism, and electrophysiological changes. These results might clarify the role of adiposity as a mediator of atrial cardiomyopathy. METHODS We used several preclinical cellular models, epicardial and subcutaneous stroma primary cell cultures from patients undergoing open heart surgery, human atrial fibroblasts, atrial cardiomyocytes derived from human induced pluripotent stem cells and isolated from adult mice, and Nav1.5 transfected Chinese hamster ovary cells. Fibrosis, glucose, mitochondrial and adipogenesis activity, gene expression, and proteomics were determined by wound healing, enzymatic, colorimetric, fluorescence assays, real-time quantitative polymerase chain reaction, and TripleTOF proteomics. Molecular changes were analyzed by Raman confocal microspectroscopy, calcium dynamics by confocal microscopy, and ion currents by patch clamp. Epicardial, subcutaneous, and atrial fibroblasts and cardiomyocytes were incubated with FABP4 at 100 ng/mL. RESULTS Our results showed that FABP4 induced fibrosis, glucose metabolism, and lipid accumulation on epicardial and subcutaneous stroma cells and atrial fibroblasts. Besides, it modified lipid content and calcium dynamics in atrial cardiomyocytes without effects on INa. CONCLUSIONS FABP4 exerts fibrotic and metabolic changes on epicardial stroma and modifies lipid content and calcium dynamic on atrial cardiomyocytes. These results suggest its possible role as an atrial cardiomyopathy mediator.
Collapse
Affiliation(s)
- Marinela Couselo-Seijas
- Cardiovascular Department, Grupo de Cardiología Traslacional (M.C.-S., X.V.-A., S.E.), IDIS, Santiago de Compostela, Spain
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain (M.C.-S., X.V.-A., J.R.G.-J.)
| | - Xocas Vázquez-Abuín
- Cardiovascular Department, Grupo de Cardiología Traslacional (M.C.-S., X.V.-A., S.E.), IDIS, Santiago de Compostela, Spain
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain (M.C.-S., X.V.-A., J.R.G.-J.)
| | - María Gómez-Lázaro
- i3S-Instituto de Investigação e Inovação em Saúde, Porto, Portugal (M.G.-L.)
- Instituto de Engenharia Biomédica, Universidade do Porto, Portugal (M.G.-L.)
| | - Laetitia Pereira
- Signaling and Cardiovascular Pathophysiology, Institut national de la santé et de la recherche médicale, UMR-S 1180, Université Paris-Saclay, Orsay, France (L.P., A.M.G.)
| | - Ana M Gómez
- Signaling and Cardiovascular Pathophysiology, Institut national de la santé et de la recherche médicale, UMR-S 1180, Université Paris-Saclay, Orsay, France (L.P., A.M.G.)
| | - Ricardo Caballero
- Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Spain (R.C., E.D.)
- Centro de investigación biomédica en red enfermedades cardiovasculares, Madrid, Spain (R.C., E.D., J.R.G.-J., S.E.)
| | - Eva Delpón
- Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Spain (R.C., E.D.)
- Centro de investigación biomédica en red enfermedades cardiovasculares, Madrid, Spain (R.C., E.D., J.R.G.-J., S.E.)
| | - Susana Bravo
- Proteomic Unit (S.B.), IDIS, Santiago de Compostela, Spain
| | - José Ramón González-Juanatey
- Universidad de Santiago de Compostela, Santiago de Compostela, Spain (M.C.-S., X.V.-A., J.R.G.-J.)
- Centro de investigación biomédica en red enfermedades cardiovasculares, Madrid, Spain (R.C., E.D., J.R.G.-J., S.E.)
- Área Cardiovascular y Unidad Coronaria, Hospital Clínico Universitario, Santiago de Compostela, Spain (J.R.G.-J.)
| | - Sonia Eiras
- Cardiovascular Department, Grupo de Cardiología Traslacional (M.C.-S., X.V.-A., S.E.), IDIS, Santiago de Compostela, Spain
- Centro de investigación biomédica en red enfermedades cardiovasculares, Madrid, Spain (R.C., E.D., J.R.G.-J., S.E.)
| |
Collapse
|
2
|
Shingu Y, Yokota I, Shichinohe T, Murakami S, Ebihara Y, Kurashima Y, Hirano S, Wakasa S. Incidence of atrial fibrillation after esophageal cancer surgery with L-carnitine use: a preliminary single-group interventional study. Surg Today 2024; 54:892-898. [PMID: 38388906 DOI: 10.1007/s00595-024-02802-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 12/22/2023] [Indexed: 02/24/2024]
Abstract
PURPOSE We aimed to investigate the POAF rate and blood FABP4 levels after perioperative L-carnitine administration in patients with esophageal cancer. METHODS L-carnitine (3 g in three divided doses) was administered to 15 patients 2 days before and 3 days after surgery. POAF during the study period and blood FABP4 levels (ELISA) before and after L-carnitine administration were evaluated. Accurate 95% confidence intervals (CI) for POAF incidence and changes in blood FABP4 levels were calculated. The preoperative predicted POAF rate was calculated using an application for esophageal cancer. The correlation between FABP4 levels and the predicted POAF rate was analyzed using Pearson's coefficient (r). RESULTS Thirteen patients completed this study. The predicted POAF rate was 24% (17%, 34%) (median; interquartile range). The actual incidence of POAF was 7.7% (95% CI: 0.2-36%). Blood FABP4 levels changed from 10.3 to 7.0 ng/mL; the average change was - 3.3 (95% CI: - 6.6 to - 0.1). A positive correlation was found between preoperative FABP4 levels and the predicted POAF rates (r = 0.564). CONCLUSIONS The POAF rate after esophageal surgery was 7.7% for L-carnitine. L-carnitine may reduce blood FABP4 levels. This preliminary study will contribute to the planning of sample sizes in future randomized trials.
Collapse
Affiliation(s)
- Yasushige Shingu
- Department of Cardiovascular Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15, Nishi-7, Kita-ku, Sapporo, Japan.
| | - Isao Yokota
- Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Toshiaki Shichinohe
- Department of Gastroenterology Surgery II, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Soichi Murakami
- Department of Gastroenterology Surgery II, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Yuma Ebihara
- Department of Gastroenterology Surgery II, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Yo Kurashima
- Department of Gastroenterology Surgery II, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Satoshi Hirano
- Department of Gastroenterology Surgery II, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Satoru Wakasa
- Department of Cardiovascular Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15, Nishi-7, Kita-ku, Sapporo, Japan
| |
Collapse
|
3
|
Mallick R, Basak S, Das RK, Banerjee A, Paul S, Pathak S, Duttaroy AK. Fatty Acids and their Proteins in Adipose Tissue Inflammation. Cell Biochem Biophys 2024; 82:35-51. [PMID: 37794302 PMCID: PMC10867084 DOI: 10.1007/s12013-023-01185-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2023] [Indexed: 10/06/2023]
Abstract
Chronic low-grade adipose tissue inflammation is associated with metabolic disorders. Inflammation results from the intertwined cross-talks of pro-inflammatory and anti-inflammatory pathways in the immune response of adipose tissue. In addition, adipose FABP4 levels and lipid droplet proteins are involved in systemic and tissue inflammation. Dysregulated adipocytes help infiltrate immune cells derived from bone marrow responsible for producing cytokines and chemokines. When adipose tissue expands in excess, adipocyte exhibits increased secretion of adipokines and is implicated in metabolic disturbances due to the release of free fatty acids. This review presents an emerging concept in adipose tissue fat metabolism, fatty acid handling and binding proteins, and lipid droplet proteins and their involvement in inflammatory disorders.
Collapse
Affiliation(s)
- Rahul Mallick
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Sanjay Basak
- Molecular Biology Division, ICMR-National Institute of Nutrition, Indian Council of Medical Research, Hyderabad, India
| | - Ranjit K Das
- Department of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, TX, USA
| | - Antara Banerjee
- Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chennai, India
| | - Sujay Paul
- Tecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc, San Pablo, Queretaro, 76130, Mexico
| | - Surajit Pathak
- Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chennai, India
| | - Asim K Duttaroy
- Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, POB 1046 Blindern, Oslo, Norway.
| |
Collapse
|
4
|
Goldman SA, Requena-Ibanez JA, Devesa A, Santos-Gallego CG, Badimon JJ, Fuster V. Uncovering the Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction. JACC. ADVANCES 2023; 2:100657. [PMID: 38938732 PMCID: PMC11198699 DOI: 10.1016/j.jacadv.2023.100657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 08/07/2023] [Accepted: 08/10/2023] [Indexed: 06/29/2024]
Abstract
Heart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure. Obesity is a modifiable risk factor of HFpEF; however, body mass index provides limited information on visceral adiposity and patients with similar anthropometrics can present variable cardiovascular risk. Epicardial adipose tissue (EAT) is the closest fat deposit to the heart and has been proposed as a biomarker of visceral adiposity. EAT may be particularly important for cardiac function, because of its location (under the pericardium) and because it acts as a metabolically active endocrine organ (which can produce both beneficial and detrimental cytokines). In this paper, the authors review the role of EAT in normal and pathologic conditions and discuss the noninvasive imaging modalities that allow its identification. This review highlights EAT implications in HFpEF and discuss new therapies that act on EAT and might also exert beneficial effects on the cardiovascular system.
Collapse
Affiliation(s)
- Sarah A. Goldman
- Department of Internal Medicine, Zucker School of Medicine at Hofstra Northwell, Lenox Hill Hospital New York, New York, New York, USA
| | - Juan Antonio Requena-Ibanez
- Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai School of Medicine, New York, New York, USA
| | - Ana Devesa
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- BioMedical Engineering and Imaging Institute (BMEII), Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Carlos G. Santos-Gallego
- Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai School of Medicine, New York, New York, USA
| | - Juan José Badimon
- Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai School of Medicine, New York, New York, USA
| | - Valentin Fuster
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| |
Collapse
|
5
|
González‐Ferrero T, Bergonti M, López‐Canoa JN, Arias FG, Eiras Penas S, Spera F, González‐Maestro A, Minguito‐Carazo C, Martínez‐Sande JL, González‐Melchor L, García‐Seara FJ, Fernández‐López JA, Álvarez‐Castro E, González‐Juanatey JR, Heidbuchel H, Sarkozy A, Rodríguez‐Mañero M. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study. ESC Heart Fail 2023; 10:3055-3066. [PMID: 37593841 PMCID: PMC10567669 DOI: 10.1002/ehf2.14448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 04/27/2023] [Accepted: 06/08/2023] [Indexed: 08/19/2023] Open
Abstract
AIMS This study aims to investigate the clinical and biochemical characteristics of patients with atrial fibrillation (AF) referred for ablation who develop arrhythmia-induced cardiomyopathy (AiCM) as well as their long-term outcomes after catheter ablation (CA). METHODS AND RESULTS A prospective multicentre study was conducted on consecutive AF patients who underwent CA. AiCM was defined as the development of heart failure in the presence of AF and an improvement of left ventricular fraction by at least 10% at 6 months after ablation. A subgroup of patients underwent peripheral and left atrial blood samples [galectin-3, fatty acid-binding protein 4 (FABP4), and soluble receptor for advanced glycation end products (sRAGE)] at the time of the procedure. Of the 769 patients who underwent AF ablation, 135 (17.56%) met the criteria for AiCM. Independent predictors of AiCM included persistent AF, male gender, left atrial volume, QRS width, active smoking, and chronic kidney disease (CKD). Biomarker analysis revealed that sRAGE, FABP4, and galectin-3 levels were not predictive of AiCM development nor did they differ between groups or predict recurrence. There were no differences in AF recurrence between patients with and without AiCM (30.83% vs. 27.77%; P = 0.392) during a median follow-up of 23.83 months (inter-quartile range 9-36). CONCLUSIONS In the subset of patients referred for AF ablation, the development of AiCM was associated with persistent AF and CKD. Biomarker analysis was not different between groups nor predicted recurrence. Patients with AiCM benefited from ablation, with a significant improvement in left ventricular ejection fraction and similar AF recurrence rates to those without AiCM.
Collapse
Affiliation(s)
- Teba González‐Ferrero
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - Marco Bergonti
- Department of CardiologyAntwerp University HospitalAntwerpBelgium
- Cardiovascular Research, GENCORUniversity of AntwerpAntwerpBelgium
- Division of Cardiology, Cardiocentro Ticino InstituteEnte Ospedaliero CantonaleLuganoSwitzerland
| | - José Nicolás López‐Canoa
- CIBERCVCarlos III Health InstituteMadridSpain
- Department of CardiologyUniversity Hospital Complex of PontevedraPontevedraSpain
| | - Federico García‐Rodeja Arias
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - Sonia Eiras Penas
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - Francesco Spera
- Department of CardiologyAntwerp University HospitalAntwerpBelgium
- Cardiovascular Research, GENCORUniversity of AntwerpAntwerpBelgium
| | - Adrián González‐Maestro
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
| | - Carlos Minguito‐Carazo
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - José Luis Martínez‐Sande
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - Laila González‐Melchor
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - Francisco Javier García‐Seara
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - Jesús Alberto Fernández‐López
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - Ezequiel Álvarez‐Castro
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - José Ramón González‐Juanatey
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| | - Hein Heidbuchel
- Department of CardiologyAntwerp University HospitalAntwerpBelgium
- Cardiovascular Research, GENCORUniversity of AntwerpAntwerpBelgium
| | - Andrea Sarkozy
- Department of CardiologyAntwerp University HospitalAntwerpBelgium
- Cardiovascular Research, GENCORUniversity of AntwerpAntwerpBelgium
| | - Moisés Rodríguez‐Mañero
- Cardiovascular Area and Coronary UnitUniversity Clinical Hospital of Santiago de CompostelaSantiago de CompostelaSpain
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS)University Clinical Hospital of Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706A CoruñaSpain
- CIBERCVCarlos III Health InstituteMadridSpain
| |
Collapse
|
6
|
Iglesias-Álvarez D, Fu X, Martínez-Cereijo JM, Agra-Bermejo RM, Veiras-Del Río S, Selas-Cobos S, Rial-Munin MV, Eiras-Mariño M, Martínez-Salgado A, Taboada-Muñiz M, Reija-López L, Souaf S, García-Carro J, Fernández-González ÁL, Adrio-Nazar B, González-Juanatey JR, Eiras S, Rodríguez-Mañero M. Clinical Profiling and Biomarkers for Post-Operative Atrial Fibrillation Prediction in Patients Undergoing Cardiac Surgery. J Clin Med 2023; 12:jcm12103565. [PMID: 37240672 DOI: 10.3390/jcm12103565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 05/17/2023] [Accepted: 05/17/2023] [Indexed: 05/28/2023] Open
Abstract
Post-operative atrial fibrillation (POAF) is the most common arrhythmia in the post-operative period after cardiac surgery. We aim to investigate the main clinical, local, and/or peripheral biochemical and molecular predictors for POAF in patients undergoing coronary and/or valve surgery. Between August 2020 and September 2022, consecutive patients undergoing cardiac surgery without previous history of AF were studied. Clinical variables, plasma, and biological tissues (epicardial and subcutaneous fat) were obtained before surgery. Pre-operative markers associated with inflammation, adiposity, atrial stretch, and fibrosis were analyzed on peripheral and local samples with multiplex assay and real-time PCR. Univariate and multivariate logistic regression analyses were performed in order to identify the main predictors for POAF. Patients were followed-up until hospital discharge. Out of 123 consecutive patients without prior AF, 43 (34.9%) developed POAF during hospitalization. The main predictors were cardiopulmonary bypass time (odds ratio (OR) 1.008 (95% confidence interval (CI), 1.002-1.013), p = 0.005), and plasma pre-operative orosomucoid levels (OR 1.008 (1.206-5.761). After studying differences regarding sex, orosomucoid was the best predictor for POAF in women (OR 2.639 (95% CI, 1.455-4.788), p = 0.027) but not in men. The results support the pre-operative inflammation pathway as a factor involved in the risk of POAF, mainly in women.
Collapse
Affiliation(s)
- Diego Iglesias-Álvarez
- Department of Cardiology, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - Xiaoran Fu
- Traslational Cardiology, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
- CIBERCV-Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, 28029 Madrid, Spain
| | - José Manuel Martínez-Cereijo
- Department of Cardiac Surgery, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - Rosa María Agra-Bermejo
- Department of Cardiology, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
- Traslational Cardiology, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
| | - Sonia Veiras-Del Río
- Department of Anaesthesia and Critical Care, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - Salomé Selas-Cobos
- Department of Anaesthesia and Critical Care, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - María Victoria Rial-Munin
- Department of Anaesthesia and Critical Care, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - María Eiras-Mariño
- Department of Anaesthesia and Critical Care, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - Adrián Martínez-Salgado
- Department of Anaesthesia and Critical Care, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - Manuel Taboada-Muñiz
- Department of Anaesthesia and Critical Care, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - Laura Reija-López
- Department of Cardiac Surgery, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - Souhayla Souaf
- Department of Cardiac Surgery, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - Javier García-Carro
- Department of Cardiac Surgery, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | | | - Belén Adrio-Nazar
- Department of Cardiac Surgery, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
| | - José Ramón González-Juanatey
- Department of Cardiology, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
- Traslational Cardiology, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
- CIBERCV-Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, 28029 Madrid, Spain
| | - Sonia Eiras
- Department of Cardiology, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
- Traslational Cardiology, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
- CIBERCV-Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, 28029 Madrid, Spain
| | - Moisés Rodríguez-Mañero
- Department of Cardiology, Complexo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain
- Traslational Cardiology, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
- CIBERCV-Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, 28029 Madrid, Spain
| |
Collapse
|
7
|
Suffee N, Baptista E, Piquereau J, Ponnaiah M, Doisne N, Ichou F, Lhomme M, Pichard C, Galand V, Mougenot N, Dilanian G, Lucats L, Balse E, Mericskay M, Le Goff W, Hatem SN. Impacts of a high-fat diet on the metabolic profile and the phenotype of atrial myocardium in mice. Cardiovasc Res 2022; 118:3126-3139. [PMID: 34971360 DOI: 10.1093/cvr/cvab367] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 12/27/2021] [Indexed: 12/16/2022] Open
Abstract
AIMS Obesity, diabetes, and metabolic syndromes are risk factors of atrial fibrillation (AF). We tested the hypothesis that metabolic disorders have a direct impact on the atria favouring the formation of the substrate of AF. METHODS AND RESULTS Untargeted metabolomic and lipidomic analysis was used to investigate the consequences of a prolonged high-fat diet (HFD) on mouse atria. Atrial properties were characterized by measuring mitochondria respiration in saponin-permeabilized trabeculae, by recording action potential (AP) with glass microelectrodes in trabeculae and ionic currents in myocytes using the perforated configuration of patch clamp technique and by several immuno-histological and biochemical approaches. After 16 weeks of HFD, obesogenic mice showed a vulnerability to AF. The atrial myocardium acquired an adipogenic and inflammatory phenotypes. Metabolomic and lipidomic analysis revealed a profound transformation of atrial energy metabolism with a predominance of long-chain lipid accumulation and beta-oxidation activation in the obese mice. Mitochondria respiration showed an increased use of palmitoyl-CoA as energy substrate. APs were short duration and sensitive to the K-ATP-dependent channel inhibitor, whereas K-ATP current was enhanced in isolated atrial myocytes of obese mouse. CONCLUSION HFD transforms energy metabolism, causes fat accumulation, and induces electrical remodelling of the atrial myocardium of mice that become vulnerable to AF.
Collapse
Affiliation(s)
- Nadine Suffee
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France
| | - Elodie Baptista
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France
| | - Jérôme Piquereau
- ICANalytics, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Maharajah Ponnaiah
- ICANalytics, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Nicolas Doisne
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France
| | - Farid Ichou
- ICANalytics, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Marie Lhomme
- Paris-Saclay University, Inserm UMRS 1180 Signaling and Cardiovascular Pathophysiology, Châtenay-Malabry, France
| | - Camille Pichard
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France
| | - Vincent Galand
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France
| | - Nathalie Mougenot
- INSERM UMR_S28, Faculté de médecine Sorbonne University, Paris, France
| | - Gilles Dilanian
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France
| | - Laurence Lucats
- Sanofi-Aventis R&D, Cardiovascular and Metabolism Research, Chilly-Mazarin, France
| | - Elise Balse
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France
| | - Mathias Mericskay
- Paris-Saclay University, Inserm UMRS 1180 Signaling and Cardiovascular Pathophysiology, Châtenay-Malabry, France
| | - Wilfried Le Goff
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Paris, France
| | - Stéphane N Hatem
- INSERM UMRS1166, ICAN-Institute of Cardiometabolism and Nutrition, Sorbonne University, Institute of Cardiology, Pitié-Salpêtrière Hospital, Paris, France
| |
Collapse
|
8
|
López-Canoa JN, Couselo-Seijas M, González-Ferrero T, Almengló C, Álvarez E, González-Maestro A, González-Melchor L, Martínez-Sande JL, García-Seara J, Fernández-López J, Kreidieh B, González-Babarro E, González-Juanatey JR, Eiras S, Rodríguez-Mañero M. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation. Int J Mol Sci 2022; 23:ijms231911107. [PMID: 36232410 PMCID: PMC9570077 DOI: 10.3390/ijms231911107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 09/18/2022] [Accepted: 09/19/2022] [Indexed: 11/16/2022] Open
Abstract
Aims: The utility of biomarkers in characterizing atrial cardiomyopathy is unclear. We aim to test the ability of biomarkers of fibrosis (galectin-3 (Gal-3)) and adiposity (fatty acid-binding protein 4 (FABP4) and leptin) to predict: (1) the presence of low-voltage areas (LVA) in the electroanatomic voltage mapping; and (2) the recurrence of atrial fibrillation (AF) after pulmonary vein isolation (PVI). Methods: Patients referred for PVI were enrolled. Areas of bipolar voltage < 0.5 mV were considered as LVA. An aggregate score incorporating AF pattern (paroxysmal, persistent and long-standing persistent) and peripheral levels of FABP4 (>20 ng/mL) was developed. Results: 299 patients were included. AF was paroxysmal in 100 (33%), persistent in 130 (43%) and long-standing persistent in 69 (23%). Multivariable analysis revealed age, left atrium area, and the proposed score as independent predictors of LVA. During a mean follow-up period of 972 ± 451 days, freedom from AF recurrence was 63%. The score incorporating AF pattern and FABP4 levels accurately predicted freedom from AF recurrence, stratifying risk into ranges from 28% (score of 1) to 68% (score of 3). Cox regression models identified the score including AF pattern + FABP4 as the best model for AF recurrence (hazard ratio 2.32; 95% CI, 1.19 to 4.5; p = 0.014). Conclusions: Traditional clinical classification of atrial cardiomyopathy may be improved by markers of adiposity (FABP4). The combination allows better prediction of the presence of LVA and AF recurrence post-PVI. Gal-3 provided no added predictive value.
Collapse
Affiliation(s)
- José Nicolás López-Canoa
- Cardiovascular Department, Hospital Complex of Pontevedra, 36071 Pontevedra, Spain
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Department of Medicine, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - Marinela Couselo-Seijas
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - Teba González-Ferrero
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Cardiovascular Department, Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - Cristina Almengló
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - Ezequiel Álvarez
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Department of Medicine, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- CIBERCV, Institute of Health Carlos III, 28220 Madrid, Spain
| | - Adrián González-Maestro
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - Laila González-Melchor
- Cardiovascular Department, Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - José Luis Martínez-Sande
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Department of Medicine, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Cardiovascular Department, Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- CIBERCV, Institute of Health Carlos III, 28220 Madrid, Spain
| | - Javier García-Seara
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Cardiovascular Department, Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- CIBERCV, Institute of Health Carlos III, 28220 Madrid, Spain
| | - Jesús Fernández-López
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Cardiovascular Department, Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - Bahij Kreidieh
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
| | - Eva González-Babarro
- Cardiovascular Department, Hospital Complex of Pontevedra, 36071 Pontevedra, Spain
| | - José Ramón González-Juanatey
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Department of Medicine, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Cardiovascular Department, Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- CIBERCV, Institute of Health Carlos III, 28220 Madrid, Spain
| | - Sonia Eiras
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- CIBERCV, Institute of Health Carlos III, 28220 Madrid, Spain
| | - Moisés Rodríguez-Mañero
- Cardiology Translational Group, Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Department of Medicine, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- Cardiovascular Department, Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain
- CIBERCV, Institute of Health Carlos III, 28220 Madrid, Spain
- Correspondence:
| |
Collapse
|
9
|
Couselo-Seijas M, Rodríguez-Mañero M, González-Juanatey JR, Eiras S. Updates on epicardial adipose tissue mechanisms on atrial fibrillation. Obes Rev 2021; 22:e13277. [PMID: 34002458 DOI: 10.1111/obr.13277] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 04/19/2021] [Indexed: 02/06/2023]
Abstract
Obesity is a well-known risk factor for atrial fibrillation (AF). Local epi-myocardial or intra-myocardial adiposity caused by aging, obesity, or cardiovascular disease (CVD) is considered to be a better predictor of the risk of AF than general adiposity. Some of the described mechanisms suggest that epicardial adipose tissue (EAT) participates in structural remodeling owing to its endocrine activity or its infiltration between cardiomyocytes. Epicardial fat also wraps up the ganglionated plexi that reach the myocardium. Although the increment of volume/thickness and activity of EAT might modify autonomic activity, autonomic system dysfunction might also change the endocrine activity of epicardial fat in a feedback response. As a result, new preventive therapeutic strategies are focused on reducing adiposity and weight loss before AF ablation or inhibiting autonomic neurotransmitter secretion on fat pads during open-heart surgery to reduce the recurrence or postoperative risk of AF. In this manuscript, we review some of the novel findings regarding the pathophysiology and associated risk factors of AF, with special emphasis on the role of EAT in the electrical, structural, and molecular mechanisms of AF initiation and maintenance. In addition, we have included a brief note provided on epicardial fat preclinical models that could be useful for identifying new therapeutic targets.
Collapse
Affiliation(s)
- Marinela Couselo-Seijas
- Translational Cardiology group, Health Research Institute, Santiago de Compostela, Spain.,University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Moisés Rodríguez-Mañero
- Translational Cardiology group, Health Research Institute, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain.,Cardiovascular Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
| | - José R González-Juanatey
- University of Santiago de Compostela, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain.,Cardiovascular Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.,Cardiology group, Health Research Institute, Santiago de Compostela, Spain
| | - Sonia Eiras
- Translational Cardiology group, Health Research Institute, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain
| |
Collapse
|
10
|
López-Canoa JN, Couselo-Seijas M, Baluja A, González-Melchor L, Rozados A, Llorente-Cortés V, de Gonzalo-Calvo D, Guerra JM, Vilades D, Leta R, Martínez-Sande JL, García-Seara FJ, Fernández-López XA, González-Juanatey JR, Eiras S, Rodríguez-Mañero M. Sex-related differences of fatty acid-binding protein 4 and leptin levels in atrial fibrillation. Europace 2021; 23:682-690. [PMID: 33319222 DOI: 10.1093/europace/euaa284] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 05/23/2020] [Accepted: 09/07/2020] [Indexed: 12/26/2022] Open
Abstract
AIMS Adiposity plays a key role in the pathogenesis of atrial fibrillation (AF). Our aim was to study the sex differences in adipokines levels according to AF burden. METHODS AND RESULTS Two independent cohorts of patients were studied: (i) consecutive patients with AF undergoing catheter ablation (n = 217) and (ii) a control group (n = 105). (i) Adipokines, oxidative stress, indirect autonomic markers, and leucocytes mRNA levels were analysed; (ii) correlation between biomarkers was explored with heatmaps and Kendall correlation coefficients; and (iii) logistic regression and random forest model were used to determine predictors of AF recurrence after ablation. Our results showed that: (i) fatty acid-binding protein 4 (FABP4) and leptin levels were higher in women than in men in both cohorts (P < 0.01). In women, FABP4 levels were higher on AF cohort (20 ± 14 control, 29 ± 18 paroxysmal AF and 31 ± 17 ng/mL persistent AF; P < 0.01). In men, leptin levels were lower on AF cohort (22 ± 15 control, 13 ± 16 paroxysmal AF and 13 ± 11 ng/mL persistent AF; P < 0.01). (ii) In female with paroxysmal AF, there was a lower acetylcholinesterase and higher carbonic anhydrase levels with respect to men (P < 0.05). (iii) Adipokines have an important role on discriminate AF recurrence after ablation. In persistent AF, FABP4 was the best predictor of recurrence after ablation (1.067, 95% confidence interval 1-1.14; P = 0.046). CONCLUSION The major finding of the present study is the sex-based differences of FABP4 and leptin levels according to AF burden. These adipokines are associated with oxidative stress, inflammatory and autonomic indirect markers, indicating that they may play a role in AF perpetuation.
Collapse
Affiliation(s)
- J N López-Canoa
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain
| | - M Couselo-Seijas
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain
| | - A Baluja
- Critical Patient Translational Research Group, Department of Anesthesiology, Intensive Care and Pain Management, University Clinical Hospital of Santiago de Compostela, Spain
| | - L González-Melchor
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain
| | - A Rozados
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain
| | - V Llorente-Cortés
- Institute of Biomedical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Spain.,Biomedical Research Institute Sant Pau (IIB Sant Pau), Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - D de Gonzalo-Calvo
- Institute of Biomedical Research of Barcelona (IIBB)-Spanish National Research Council (CSIC), Spain.,Biomedical Research Institute Sant Pau (IIB Sant Pau), Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - J M Guerra
- CIBERCV, Institute of Health Carlos III, Madrid, Spain.,Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica-Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni M a Claret, Spain
| | - D Vilades
- Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica-Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni M a Claret, Spain
| | - R Leta
- Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica-Sant Pau, Universitat Autònoma de Barcelona, Sant Antoni M a Claret, Spain
| | - J L Martínez-Sande
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - F J García-Seara
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - X A Fernández-López
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain
| | - J R González-Juanatey
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - S Eiras
- Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| | - M Rodríguez-Mañero
- Cardiovascular area and Coronary Unit, University Clinical Hospital of Santiago de Compostela, Spain.,Translational Cardiology Group, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), Travesía da Choupana s/n, Santiago de Compostela, 15706 A Coruña, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|
11
|
Couselo-Seijas M, Lopez-Canoa JN, Fernandez ÁL, González-Melchor L, Seoane LM, Duran-Muñoz D, Rozados-Luis A, González-Juanatey JR, Rodríguez-Mañero M, Eiras S. Inflammatory and lipid regulation by cholinergic activity in epicardial stromal cells from patients who underwent open-heart surgery. J Cell Mol Med 2020; 24:10958-10969. [PMID: 32767737 PMCID: PMC7521153 DOI: 10.1111/jcmm.15727] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 06/26/2020] [Accepted: 07/18/2020] [Indexed: 01/14/2023] Open
Abstract
The modulation of acetylcholine (ACh) release by botulinum toxin injection into epicardial fat diminishes atrial fibrillation (AF) recurrence. These results suggest an interaction between autonomic imbalance and epicardial fat as risk factors of AF. Our aim was to study the inflammatory, lipidic and fibroblastic profile of epicardial stroma from patients who underwent open‐heart surgery, their regulation by cholinergic activity and its association with AF. We performed in vitro and ex vivo assays from paired subcutaneous and epicardial stromal cells or explants from 33 patients. Acute ACh effects in inflammation and lipid‐related genes were analysed by qPCR, in intracellular calcium mobilization were performed by Fluo‐4 AM staining and in neutrophil migration by trans‐well assays. Chronic ACh effects on lipid accumulation were visualized by AdipoRed. Plasma protein regulation by parasympathetic denervation was studied in vagotomized rats. Our results showed a higher pro‐inflammatory profile in epicardial regarding subcutaneous stromal cells. Acute ACh treatment up‐regulated monocyte chemoattractant protein 1 levels. Chronic ACh treatment improved lipid accumulation within epicardial stromal cells (60.50% [22.82‐85.13] vs 13.85% [6.17‐23.16], P < .001). Additionally, patients with AF had higher levels of fatty acid‐binding protein 4 (1.54 ± 0.01 vs 1.47 ± 0.01, P = .005). Its plasma levels were pronouncedly declined in vagotomized rats (2.02 ± 0.21 ng/mL vs 0.65 ± 0.23 ng/mL, P < .001). Our findings support the characterization of acute or chronic cholinergic activity on epicardial stroma and its association with AF.
Collapse
Affiliation(s)
- Marinela Couselo-Seijas
- Translational Cardiology group, Health Research Institute, Santiago de Compostela, Spain.,University of Santiago de Compostela, Santiago de Compostela, Spain
| | - José N Lopez-Canoa
- Translational Cardiology group, Health Research Institute, Santiago de Compostela, Spain.,Cardiovascular Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
| | - Ángel L Fernandez
- University of Santiago de Compostela, Santiago de Compostela, Spain.,Heart Surgery Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain
| | - Laila González-Melchor
- Cardiology Group, Health Research Institute, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain
| | - Luisa M Seoane
- Endocrine Physiopathology Group, Health Research Institute, Santiago de Compostela, Spain.,CIBERobn, Madrid, Spain
| | - Darío Duran-Muñoz
- Heart Surgery Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain
| | - Adriana Rozados-Luis
- Translational Cardiology group, Health Research Institute, Santiago de Compostela, Spain
| | - José Ramón González-Juanatey
- University of Santiago de Compostela, Santiago de Compostela, Spain.,Cardiovascular Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.,Cardiology Group, Health Research Institute, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain
| | - Moisés Rodríguez-Mañero
- Translational Cardiology group, Health Research Institute, Santiago de Compostela, Spain.,Cardiovascular Department, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain
| | - Sonia Eiras
- Translational Cardiology group, Health Research Institute, Santiago de Compostela, Spain.,CIBERCV, Madrid, Spain
| |
Collapse
|
12
|
von Jeinsen B, Ritzen L, Vietheer J, Unbehaun C, Weferling M, Liebetrau C, Hamm CW, Rolf A, Keller T. The adipokine fatty-acid binding protein 4 and cardiac remodeling. Cardiovasc Diabetol 2020; 19:117. [PMID: 32727561 PMCID: PMC7392717 DOI: 10.1186/s12933-020-01080-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 07/02/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Previous publications about the association between fatty-acid binding protein 4 (FABP4) and cardiac remodeling have reported different, both beneficial and harmful, associations. Aim of the present investigation was to evaluate the association of FABP4 with parameters of myocardial remodeling defined by cardiac magnetic resonance imaging (CMR). METHODS We investigated plasma FABP4 levels in 331 patients (71% men, mean age 63±13 years) with preserved left ventricular ejection fraction (LVEF ≥ 55%) who underwent a CMR examination. We used linear cox regression to investigate associations between FABP4 and left ventricular end-diastolic diameter (LVEDD), right ventricular end-diastolic diameter (RVEDD), relative wall thickness (RWT), left ventricular mass index (LVMI), and LVEF (unadjusted and adjusted for age, sex, body mass index, cardiac biomarkers, and comorbidities). RESULTS FABP4 levels were associated with lower LVMI and higher NT-proBNP levels in an adjusted model. The inverse association between FABP4 and LVMI was more pronounced in lower FABP4 levels, whereas the positive association between FABP4 and NT-proBNP was more pronounced in relatively high NT-proBNP levels. CONCLUSIONS Possible beneficial and harmful associations between FABP4 and left ventricular size have been reported. Our results suggest a beneficial association with LVMI (more pronounced in lower FABP4 levels) but a harmful association with NT-proBNP (more pronounced in higher FABP4 levels). Therefore, our results might indicate a potential dose-dependent association of FABP4, but this observation needs further investigation in larger study samples.
Collapse
Affiliation(s)
- Beatrice von Jeinsen
- Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany.,German Centre for Cardiovascular Research (DZHK), Center Rhein-Main, Berlin, Germany
| | - Lisa Ritzen
- Department of Internal Medicine I, Cardiology, Justus-Liebig-University Giessen, Klinikstrasse 33, 35392, Giessen, Germany
| | - Julia Vietheer
- Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany
| | - Claudia Unbehaun
- Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany
| | - Maren Weferling
- Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany
| | - Christoph Liebetrau
- Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany.,Department of Internal Medicine I, Cardiology, Justus-Liebig-University Giessen, Klinikstrasse 33, 35392, Giessen, Germany.,German Centre for Cardiovascular Research (DZHK), Center Rhein-Main, Berlin, Germany
| | - Christian W Hamm
- Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany.,Department of Internal Medicine I, Cardiology, Justus-Liebig-University Giessen, Klinikstrasse 33, 35392, Giessen, Germany.,German Centre for Cardiovascular Research (DZHK), Center Rhein-Main, Berlin, Germany
| | - Andreas Rolf
- Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany.,Department of Internal Medicine I, Cardiology, Justus-Liebig-University Giessen, Klinikstrasse 33, 35392, Giessen, Germany.,German Centre for Cardiovascular Research (DZHK), Center Rhein-Main, Berlin, Germany
| | - Till Keller
- Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, 61231, Bad Nauheim, Germany. .,Department of Internal Medicine I, Cardiology, Justus-Liebig-University Giessen, Klinikstrasse 33, 35392, Giessen, Germany. .,German Centre for Cardiovascular Research (DZHK), Center Rhein-Main, Berlin, Germany.
| |
Collapse
|